Arcellx, Inc. (ACLX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Redwood City, MD, United States. The current CEO is Rami Elghandour.
ACLX has IPO date of 2022-02-04, 163 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $6.72B.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for patients with cancer and other serious diseases. The company's lead candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, while its pipeline includes ACLX-001, a dual-targeting immunotherapy combining ARC-T cells and SparX proteins, as well as additional programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Founded in 2014 and headquartered in Gaithersburg, Maryland, Arcellx focuses on advancing next-generation cell and protein-based therapies to address unmet medical needs in oncology.
